The company manufactures and trades specialty chemicals, active pharmaceutical ingredients (APIs), and generic drug formulations for the pharmaceutical, agrochemical, and industrial sectors. It operates through a mix of in-house manufacturing, contract manufacturing partnerships, and domestic distribution networks.
The company operates in a highly commoditized segment of the chemical and pharma industry, evidenced by extremely thin net margins of approximately 2%. While they have filed for patents on manufacturing processes for Vitamins B1 and B6, the financial metrics show no durable pricing power or scale advantage, with ROCE hovering near the cost of capital.
Management is aggressively pursuing empire-building through the acquisition of small, underperforming subsidiaries and the setup of multiple foreign entities before proving the core business's cash-flow viability. Significant capital is tied up in working capital, leading to negative cash conversion and a heavy reliance on debt and equity dilution to fund operations.
The collapse was driven by a classic liquidity trap where accounting profits never materialized into cash. The company's aggressive expansion into foreign subsidiaries and unproven acquisitions, funded by high-interest debt and equity dilution, eventually hit a wall when the negative cash conversion cycle became unsustainable. As interest rates rose or credit tightened, the razor-thin 2% margins were insufficient to service the 1.84 debt-to-equity load, leading to a credit crunch. The frequent turnover of CFOs and internal control weaknesses flagged in audits were early warnings of the eventual financial restatements that wiped out shareholder equity.
RichFakir rates Sudarshan Pharma Industries Ltd's business quality as poor — 32/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Sudarshan Pharma Industries Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Sudarshan Pharma Industries Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Sudarshan Pharma Industries Ltd's fair value is about ₹5 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →